A Phase Ib/II Trial of SHR-1701 Combined With Gemcitabine and Albumin Paclitaxel in First-line Treatment of Subjects With Advanced/Metastatic Pancreatic Cancer
Latest Information Update: 17 Jan 2024
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Retlirafusp alfa (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 10 Jan 2024 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results (As of data cutoff on Nov 19, 2021)presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 26 Sep 2021 Status changed from recruiting to active, no longer recruiting.